Zymeworks (NASDAQ:ZYME) Board of Directors Approves Stock Repurchase Plan

Zymeworks (NASDAQ:ZYME – Get Free Report) declared that its Board of Directors has authorized a share buyback plan on Monday, November 16th, RTT News reports. The company plans to buy back $200 million in outstanding shares. This buyback authorization authorizes the company to buy up to 10.9% of its shares through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Zymeworks Stock Down 2.3%

NASDAQ ZYME opened at $25.84 on Wednesday. The stock’s 50-day moving average price is $27.22 and its 200-day moving average price is $25.52. Zymeworks has a 52 week low of $21.52 and a 52 week high of $31.97. The company has a market capitalization of $1.78 billion, a P/E ratio of 49.69 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. The firm had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The business’s quarterly revenue was up 828.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.26) EPS. Research analysts anticipate that Zymeworks will post 1.31 EPS for the current year.

Analyst Ratings Changes

ZYME has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Thursday, October 15th. B. Riley Financial reiterated a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Citizens Jmp increased their price target on Zymeworks from $32.00 to $39.00 and gave the company a “market outperform” rating in a report on Friday, November 13th. JPMorgan Chase & Co. raised their price target on Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Finally, HC Wainwright raised their price target on Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Get Our Latest Stock Report on ZYME

Insider Buying and Selling

In other Zymeworks news, insider Paul Moore sold 39,741 shares of Zymeworks stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the transaction, the insider owned 33,756 shares of the company’s stock, valued at $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president directly owned 23,205 shares in the company, valued at $599,849.25. This represents a 37.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by company insiders.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Featured Stories

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.